SEARCH

SEARCH BY CITATION

REFERENCES

  • Ackley A, Lenox A, Stapleton K, Knowling S, Lu T, Sabir KS, Vogt PK, Morris KV. 2013. An algorithm for generating small RNAs capable of epigenetically modulating transcriptional gene silencing and activation in human cells. Mol Ther Nucleic Acids 2:e104.
  • Alisch RS, Wang T, Chopra P, Visootsak J, Conneely KN, Warren ST. 2013. Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to the FMR1 locus. BMC Med Genet 14:18.
  • Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, Holden JJA, Yang KT, Lee C, Hudson R, Gorwill H, Nolin SL, Glicksman A, Jenkins EC, Brown WT, Howard-Peebles PN, Becchi C, Cummings E, Fallon L, Seitz S, Black SH, Vianna-Morgante AM, Costa SS, Otto PA, Mingroni-Netto RC, Murray A, Webb J, MacSwinney F, Dennis N, Jacobs PA, Syrrou M, Georgiou J, Patsalis PC, Giovannucci Uzielli ML, Guarducci S, Lapi E, Lecconi A, Ricci U, Ricotti G, Biondi C, Scarselli B, Vieri F. 1999. Fragile X premutation is a significant risk factor for premature ovarian failure: The international collaborative POF in fragile X study—Preliminary data. Am J Med Genet 83:322325.
  • Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. 1999. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature Genet 23:185188.
  • Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, Boninsegna A, Villanova M, Bertini E, Pini A, Neri G, Brahe C. 2004. Phenylbutyrate increases SMN expression in vitro: Relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 12:5965.
  • Angart P, Vocelle D, Chan C, Walton SP. 2013. Design of siRNA therapeutics from the molecular scale. Pharmaceuticals (Basel) 6:440468.
  • Bagni C, Oostra B. 2013. Fragile X syndrome: From protein function to therapy. Am J Med Genet Part A (this issue).
  • Bar-Nur O, Caspi I, Benvenisty N. 2012. Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives. J Mol Cell Biol 4:180183.
  • Berdasco M, Esteller M. 2013. Genetic syndromes caused by mutations in epigenetic genes. Hum Genet 132:359383.
  • Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. 2009. An operational definition of epigenetics. Genes Dev 23:781783.
  • Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ, McMahon S, Karlsson EK, Kulbokas EJ, Gingeras TR, Schreiber SL, Lander ES. 2005. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120:169181.
  • Bestor TH. 2000. The DNA methyltransferases of mammals. Hum Mol Genet 9:23952402.
  • Bodai L, Pallos J, Thompson LM, Marsh JL. 2012. Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington's disease. Neurodegener Dis 9:104106.
  • Buiting K. 2010. Prader–Willi syndrome and Angelman syndrome. Am J Med Genet Part C 154C:365376.
  • Burdge GC, Hoile SP, Uller T, Thomas NA, Gluckman PD, Hanson MA, Lillycrop KA. 2011. Progressive, transgenerational changes in offspring phenotype and epigenotype following nutritional transition. PLoS ONE 6:e28282.
  • Cameron EE, Bachman KE, Myöhänen S, Herman JB, Baylin SB. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103107.
  • Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. 2002. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:10391043.
  • Castel SE, Martienssen RA. 2013. RNA interference in the nucleus: Roles for small RNAs in transcription, epigenetics and beyond. Nat Rev Genet 14:100112.
  • Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. 2001. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 98:98089813.
  • Chen WL, Lin JW, Huang HJ, Wang SM, Su MT, Lee-Chen GJ, Chen CM, Hsieh-Li HM. 2008. SCA8 mRNA expression suggests an antisense regulation of KLHL1 and correlates to SCA8 pathology. Brain Res 1233:176184.
  • Chiurazzi P, Neri G. 2003. Reactivation of silenced genes and transcriptional therapy. Cytogenet Genome Res 100:5664.
  • Chiurazzi P, Pomponi MG, Willemsen R, Oostra BA, Neri G. 1998. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet 7:109113.
  • Chiurazzi P, Pomponi MG, Pietrobono R, Bakker CE, Neri G, Oostra BA. 1999. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet 8:23172323.
  • Choufani S, Shuman C, Weksberg R. 2010. Beckwith–Wiedemann syndrome. Am J Med Genet Part C 154C:343354.
  • Coffee B, Zhang F, Ceman S, Warren ST, Reines D. 2002. Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome. Am J Hum Genet 71:923932.
  • Collins SC, Bray SM, Suhl JA, Cutler DJ, Coffee B, Zwick ME, Warren ST. 2010. Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed males. Am J Med Genet Part A 152A:25122520.
  • Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, Le Coz M, Devarajan K, Wessels A, Soprano D, Abramowitz LK, Bartolomei MS, Rambow F, Bassi MR, Bruno T, Fanciulli M, Renner C, Klein-Szanto AJ, Matsumoto Y, Kobi D, Davidson I, Alberti C, Larue L, Bellacosa A. 2011. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146:6779.
  • Crawford DC, Meadows KL, Newman JL, Taft LF, Pettay DL, Gold LB, Hersey SJ, Hinkle EF, Stanfield ML, Holmgreen P, Yeargin-Allsopp M, Boyle C, Sherman SL. 1999. Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population. Am J Hum Genet 64:495507.
  • Dalton SR, Bellacosa A. 2012. DNA Demethylation by TDG. Epigenomics 4:459467.
  • De Biase I, Chutake YK, Rindler PM, Bidichandani SI. 2009. Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS ONE 4:e7914.
  • Debacker K, Winnepenninckx B, Longman C, Colgan J, Tolmie J, Murray R, van Luijk R, Scheers S, Fitzpatrick D, Kooy F. 2007. The molecular basis of the folate-sensitive fragile site FRA11A at 11q13. Cytogenet Genome Res 119:914.
  • DeBoulle K, Verkerk AJ, Reyniers E, Vits L, Hendrickx J, Van Roy B, Van den Bos F, de Graaff E, Oostra BA, Willems PJ. 1993. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nature Genet 3:3135.
  • Dong A, Yoder JA, Zhang X, Zhou L, Bestor TH, Cheng X. 2001. Structure of human DNMT2, an enigmatic DNA methyl-transferase homolog that displays denaturant-resistant binding to DNA. Nucleic Acids Res 29:439448.
  • Doros L, Yang J, Dehner L, Rossi CT, Skiver K, Jarzembowski JA, Messinger Y, Schultz KA, Williams G, André N, Hill DA. 2012. DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome. Pediatr Blood Cancer 59:558560.
  • Ehrlich M, Gama Sosa MA, Huang L-H, Midgett RM, Kuo KC, McCune RA, Gehrke C. 1982. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues or cells. Nucleic Acids Res 10:27092721.
  • Eichler EE, Richards S, Gibbs RA, Nelson DL. 1993. Fine structure of the human FMR1 gene. Hum Mol Genet 2:11471153.
  • Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, Amit A, Yaron Y, Eden A, Yanuka O, Benvenisty N, Ben-Yosef D. 2007. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1:568577.
  • Feng Y, Zhang F, Lokey LK, Chastain JL, Lakkis L, Eberhart D, Warren ST. 1995. Translational suppression by trinucleotide repeat expansion at FMR1. Science 268:731734.
  • Fernandez-Carvajal I, Lopez Posadas B, Pan R, Raske C, Hagerman PJ, Tassone F. 2009. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn 11:306310.
  • Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806811.
  • Friso S, Choi SW. 2002. Gene-nutrient interactions and DNA methylation. J Nutr 132:2382S2387S.
  • Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST. 2005. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 25:47274741.
  • Gibbons RJ, Picketts DJ, Villard L, Higgs DR. 1995. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell 80:837845.
  • Gnyszka A, Jastrzebski Z, Flis S. 2013. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 33:29892996.
  • Guo JU, Su Y, Zhong C, Ming GL, Song H. 2011. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145:423434.
  • Gurrieri F, Zollino M, Oliva A, Pascali V, Orteschi D, Pietrobono R, Camporeale A, Coll Vidal M, Partemi S, Brugada R, Bellocci F, Neri G. 2013. Mild Beckwith–Wiedemann and severe long-QT syndrome due to deletion of the imprinting center 2 on chromosome 11p. Eur J Hum Genet 21:965969.
  • Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ. 2001. Intention tremor, Parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57:127130.
  • Huber KM, Gallagher SM, Warren ST, Bear MF. 2002. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99:77467750.
  • International Human Genome Sequencing Consortium. 2001. Initial sequencing and analysis of the human genome. Nature 409:860921.
  • Irwin SA, Galvez R, Greenough WT. 2000. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10:10381044.
  • Ito S, Li S, Dai Q, Wu SC, Collins SB, Swenberg JA, He C, Zhang Y. 2011. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333:13001303.
  • Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R. 1997. Mutagenicity of 5-aza-2*-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci USA 94:46814685.
  • Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B. 2011. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3:64ra1.
  • Jiang J, Jing Y, Cost GJ, Chiang JC, Kolpa HJ, Cotton AM, Carone DM, Carone BR, Shivak DA, Guschin DY, Pearl JR, Rebar EJ, Byron M, Gregory PD, Brown CJ, Urnov FD, Hall LL, Lawrence JB. 2013. Translating dosage compensation to trisomy 21. Nature 500:296300.
  • Jones PA, Taylor SM. 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:8593.
  • Jones C, Müllenbach R, Grossfeld P, Auer R, Favier R, Chien K, James M, Tunnacliffe A, Cotter F. 2000. Co-localisation of CCG repeats and chromosome deletion breakpoints in Jacobsen syndrome: Evidence for a common mechanism of chromosome breakage. Hum Mol Genet 9:12011208.
  • Kemp S, Wei HM, Lu JF, Braiterman LT, McGuinness MC, Moser AB, Watkins PA, Smith KD. 1998. Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy. Nat Med 4:12611268.
  • Klein CJ, Botuyan MV, Wu Y, Ward CJ, Nicholson GA, Hammans S, Hojo K, Yamanishi H, Karpf AR, Wallace DC, Simon M, Lander C, Boardman LA, Cunningham JM, Smith GE, Litchy WJ, Boes B, Atkinson EJ, Middha S, Dyck PJB, Parisi JE, Mer G, Smith DI, Dyck PJ. 2011. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet 43:595600.
  • Knight SJ, Flannery AV, Hirst MC, Campbell L, Christodoulou Z, Phelps SR, Pointon J, Middleton-Price HR, Barnicoat A, Pembrey ME, Holland J, Oostra BA, Bobrow M, Davies KE. 1993. Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. Cell 74:127134.
  • Kumari D, Usdin K. 2010. The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome. Hum Mol Genet 19:46344642.
  • Ladd PD, Smith LE, Rabaia NA, Moore JM, Georges SA, Hansen RS, Hagerman RJ, Tassone F, Tapscott SJ, Filippova GN. 2007. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 16:31743187.
  • Lalani SR, Safiullah AM, Fernbach SD, Harutyunyan KG, Thaller C, Peterson LE, McPherson JD, Gibbs RA, White LD, Hefner M, Davenport SLH, Graham JM Jr, Bacino CA, Glass NL, Towbin JA, Craigen WJ, Neish SR, Lin AE, Belmont JW. 2006. Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome and genotype–phenotype correlation. Am J Hum Genet 78:303314.
  • Lanni S, Goracci M, Borrelli L, Mancano G, Chiurazzi P, Moscato U, Ferrè F, Helmer-Citterich M, Tabolacci E, Neri G. 2013. Role of CTCF protein in regulating FMR1 locus transcription. PLoS Genet 9:e1003601.
  • Lee MP, DeBaun MR, Mitsuya K, Galonek HL, Brandenburg S, Oshimura M, Feinberg AP. 1999. Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith–Wiedemann syndrome and is independent of insulin-like growth factor II imprinting. Proc Natl Acad Sci USA 96:52035208.
  • Lubs HA. 1969. A marker X chromosome. Am J Hum Genet 21:231244.
  • Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ. 1997. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251260.
  • Mattick JS, Amaral PP, Dinger ME, Mercer TR, Mehler MF. 2009. RNA regulation of epigenetic processes. BioEssays 31:5159.
  • Mayer W, Niveleau A, Walter J, Fundele R, Haaf T. 2000. Demethylation of the zygotic paternal genome. Nature 403:501502.
  • McGhee JD, Ginder GD. 1979. Specific DNA methylation sites in the vicinity of the chicken beta-globin genes. Nature 280:419420.
  • Morris KV. 2009. Long antisense non-coding RNAs function to direct epigenetic complexes that regulate transcription in human cells. Epigenetics 4:296301.
  • Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386389.
  • Nancarrow JK, Holman K, Mangelsdorf M, Hori T, Denton M, Sutherland GR, Richards RI. 1995. Molecular basis of p(CCG)n repeat instability at the FRA16A fragile site locus. Hum Mol Genet 4:367372.
  • Naumann A, Hochstein N, Weber S, Fanning E, Doerfler W. 2009. A distinct DNA-methylation boundary in the 5′-upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am J Hum Genet 85:606616.
  • Nolin SL, Sah S, Glicksman A, Sherman SL, Allen E, Berry-Kravis E, Tassone F, Yrigollen C, Cronister A, Jodah M, Ersalesi N, Dobkin C, Brown WT, Shroff R, Latham GJ, Hadd AG. 2013. Fragile X AGG analysis provides new risk predictions for 45–69 repeat alleles. Am J Med Genet Part A 161A:771778.
  • Oberlé I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boué J, Bertheas MF, Mandel JL. 1991. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252:10971102.
  • O'Hagan HM, Mohammad HP, Baylin SB. 2008. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet 4:e1000155.
  • Ørstavik KH, Knudsen GP, Nordgarden H, Ormerod E, Strømme P, Lazarou LP, Rosser LG, Prescott T, Houge G. 2007. Severe hypohidrotic ectodermal dysplasia in a girl caused by a de novo 9;X insertion that includes XIST and disrupts the EDA gene. Am J Med Genet Part A 143A:15101513.
  • Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. 2010. Targeting of 5-aza-2-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucl Acids Res 38:43134324.
  • Peng JC, Lin H. 2013. Beyond transposons: The epigenetic and somatic functions of the Piwi-piRNA mechanism. Curr Opin Cell Biol 25:190194.
  • Pietrobono R, Pomponi MG, Tabolacci E, Oostra B, Chiurazzi P, Neri G. 2002. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res 30:32783285.
  • Pietrobono R, Tabolacci E, Zalfa F, Zito I, Terracciano A, Moscato U, Bagni C, Oostra B, Chiurazzi P, Neri G. 2005. Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet 14:267277.
  • Pirooznia SK, Elefant F. 2013. Targeting specific HATs for neurodegenerative disease treatment: Translating basic biology to therapeutic possibilities. Front Cell Neurosci 7:30.
  • Pirozzi F, Tabolacci E, Neri G. 2011. The FRAXopathies: Definition, overview, and update. Am J Med Genet Part A 155A:18031816.
  • Plenge RM, Hendrich BD, Schwartz C, Arena JF, Naumova A, Sapienza C, Winter RM, Willard HF. 1997. A promoter mutation in the XIST gene in two unrelated families with skewed X-chromosome inactivation. Nat Genet 17:353356.
  • Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C. 2002. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA 8:14821488.
  • Rajasethupathy P, Antonov I, Sheridan R, Frey S, Sander C, Tuschl T, Kandel ER. 2012. A role for neuronal piRNAs in the epigenetic control of memory-related synaptic plasticity. Cell 149:693707.
  • Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD, Jenuwein T. 2000. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406:593599.
  • Reik W, Dean W, Walter J. 2001. Epigenetic reprogramming in mammalian development. Science 293:10891093.
  • Ritchie RJ, Knight SJ, Hirst MC, Grewal PK, Bobrow M, Cross GS, Davies KE. 1994. The cloning of FRAXF: Trinucleotide repeat expansion and methylation at a third fragile site in distal Xqter. Hum Mol Genet 3:21152121.
  • Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. 1998. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:58585868.
  • Rougeulle C, Cardoso C, Fontés M, Colleaux L, Lalande M. 1998. An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript. Nat Genet 19:1516.
  • Saha A, Wittmeyer J, Cairns BR. 2006. Chromatin remodelling: The industrial revolution of DNA around histones. Nat Rev Mol Cell Biol 7:437447.
  • Sarafidou T, Kahl C, Martinez-Garay I, Mangelsdorf M, Gesk S, Baker E, Kokkinaki M, Talley P, Maltby EL, French L, Harder L, Hinzmann B, Nobile C, Richkind K, Finnis M, Deloukas P, Sutherland GR, Kutsche K, Moschonas NK, Siebert R, Gécz J, European Collaborative Consortium for the Study of ADLTE. 2004. Folate-sensitive fragile site FRA10A is due to an expansion of a CGG repeat in a novel gene, FRA10AC1, encoding a nuclear protein. Genomics 84:6981.
  • Shaw MA, Chiurazzi P, Romain DR, Neri G, Gécz J. 2002. A novel gene, FAM11A, associated with the FRAXF CpG island is transcriptionally silent in FRAXF full mutation. Eur J Hum Genet 10:767772.
  • Sheridan SD, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L, Loring JF, Haggarty SJ. 2011. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS ONE 6:e26203.
  • Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, Hewitt M, Jenkinson H, King D, Morland B, Pizer B, Prescott K, Saggar A, Side L, Traunecker H, Vaidya S, Ward P, Futreal PA, Vujanic G, Nicholson AG, Sebire N, Turnbull C, Priest JR, Pritchard-Jones K, Houlston R, Stiller C, Stratton MR, Douglas J, Rahman N. 2011. DICER1 syndrome: Clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 48:273278.
  • Smeets HJ, Smits AP, Verheij CE, Theelen JP, Willemsen R, van de Burgt I, Hoogeveen AT, Oosterwijk JC, Oostra BA. 1995. Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet 4:21032108.
  • Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM. 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739743.
  • Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:4145.
  • Strahl BD, Grant PA, Briggs SD, Sun ZW, Bone JR, Caldwell JA, Mollah S, Cook RG, Shabanowitz J, Hunt DF, Allis CD. 2002. Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. Mol Cell Biol 22:12981306.
  • Suzuki MM, Bird A. 2008. DNA methylation landscapes: Provocative insights from epigenomics. Nat Rev Genet 9:465476.
  • Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genet 31:141149.
  • Tabish AM, Poels K, Hoet P, Godderis L. 2012. Epigenetic factors in cancer risk: Effect of chemical carcinogens on global DNA methylation pattern in human TK6 cells. PLoS ONE 7:e34674.
  • Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, Neri G. 2005. Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet 13:641648.
  • Tabolacci E, Moscato U, Zalfa F, Bagni C, Chiurazzi P, Neri G. 2008a. Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet 16:14871498.
  • Tabolacci E, De Pascalis I, Accadia M, Terracciano A, Moscato U, Chiurazzi P, Neri G. 2008b. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenet Genomics 18:738741.
  • Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, Marzullo E, Romeo G, Vallee L, Veneselli E, Cocchi E, Garbarino E, Moscato U, Chiurazzi P, D'Iddio S, Calvani M, Neri G. 2008. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet Part A 146A:803812.
  • Ulrey CL, Liu L, Andrews LG, Tollefsbol TO. 2005. The impact of metabolism on DNA methylation. Hum Mol Genet 4:R139R147.
  • Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. 2010. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 6:407411.
  • Valor LM, Viosca J, Lopez-Atalaya JP, Barco A. 2013. Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. Curr Pharm Des 19:50515064.
  • Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DPA, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang F, Eussen BE, van Ommen G-JB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST. 1991. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905914.
  • Waddington CH. 1942. The epigenotype. Endeavour 1:1820.
  • Wang Z, Yao H, Lin S, Zhu X, Shen Z, Lu G, Poon WS, Xie D, Lin MC, Kung HF. 2012. Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett 331:110.
  • Willemsen R, Bontekoe CJ, Severijnen LA, Oostra BA. 2002. Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum Genet 110:601605.
  • Winkelmann J, Lin L, Schormair B, Kornum BR, Faraco J, Plazzi G, Melberg A, Cornelio F, Urban AE, Pizza F, Poli F, Grubert F, Wieland T, Graf E, Hallmayer J, Strom TM, Mignot E. 2012. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet 21:22052210.
  • Winnepenninckx B, Debacker K, Ramsay J, Smeets D, Smits A, FitzPatrick DR, Kooy RF. 2007. CGG-repeat expansion in the DIP2B gene is associated with the fragile site FRA12A on chromosome 12q13.1. Am J Hum Genet 80:221231.
  • Xu G-L, Bestor TH, Bourc'his D, Hsieh C-L, Tommerup N, Bugge M, Hulten M, Qu X, Russo JJ, Viegas-Pequignot E. 1999. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402:187191.